Uppal Manpreet has officially reported a change in his stock ownership following his resignation from the Board of Directors at GridAI Technologies Corp. This significant update, filed on October 28, 2026, sheds light on the ongoing transformations within the company's leadership.

Uppal Manpreet is associated with GridAI Technologies Corp., which operates in the electric and other services combined sector. The company is based in Boca Raton, Florida, and has undergone several name changes in the past, previously known as Entero Therapeutics, Inc., First Wave BioPharma, Inc., and AzurRx BioPharma, Inc. The most recent filing indicates that Manpreet was granted 20,000 restricted stock units under the company's 2020 Omnibus Equity Incentive Plan, which vested in full on the date of grant, just prior to his resignation.

The filing states, "The Reporting Person was granted 20,000 restricted stock units under the Issuer's 2020 Omnibus Equity Incentive Plan, as amended, in recognition of service on the Board of Directors, which vested in full on the date of grant, immediately prior to the Reporting Person's resignation from the Board of Directors effective October 19, 2026." Following this transaction, Manpreet now owns a total of 60,000 shares of common stock in GridAI Technologies Corp.

This change may affect various stakeholders, including investors and analysts, who closely monitor the governance and leadership stability within the company. The resignation of a board member can often raise questions about the company's future direction and management strategies.

The filing does not say what happens next for either Manpreet or GridAI Technologies Corp. However, the implications of this change could resonate throughout the company's operations and governance structure.